Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body

Sana Biotechnology has filed for an initial public offering, less than three years after it was founded. It is the latest life science company out of Seattle to go public, following successful IPOs by Athira Pharma and Silverback Therapeutics in 2020. The company is currently developing gene and cell therapies that could be used to combat a variety of diseases, and previously raised more than $700 million in venture capital.